trending Market Intelligence /marketintelligence/en/news-insights/trending/MmM6KBrDHkFmAF18Tu7YBQ2 content esgSubNav
In This List

CHMP recommends Bristol-Myers' Yervoy for pediatric skin cancer patients

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


CHMP recommends Bristol-Myers' Yervoy for pediatric skin cancer patients

Bristol-Myers Squibb Co. said a panel of the European Medicines Agency recommended the approval of Yervoy for treating skin cancer in pediatric patients.

The backing from the EMA's Committee for Medicinal Products for Human Use covers the use of Yervoy, or ipilimumab, in unresectable or metastatic melanoma patients aged 12 years and older.

Bristol-Myers' Yervoy is already approved for multiple cancer indications. The monoclonal antibody works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.